Skip to content
MondayNightIBD
First-line Treatment with IL-23p19 agents for Patients with Ulcerative Colitis
March 17, 2025 ~ Waqqas Afif, MD
**Pre-assessment**
Before you participate in this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
Where are you in your career?
(Required.)
IBD Specialist
General GI
Fellow/Trainee
APP
PharmD
Other (please specify)
*
2.
Which of the following drug class / MOA is recommended as a first line therapy in moderate to severe Crohn’s disease?
(Required.)
Mesalamine (5-ASA)
Thiopurines or Methotrexate
Biologic
Any of the above
*
3.
Young patient with isolated small bowel Crohn’s. As you recommend a specific drug class, its mainly based on what type fo studies in small bowel CD?
(Required.)
Head to head drug comparison
RCT in SB Crohn’s
Large Retrospective studies in SB crohns
Overall drug efficacy in Crohn’s disease
4.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name
🔗
Proceed to activity on X/MondayNightIBD
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
